Clinical Trial Update: Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Zimura to sham in autosomal recessive Stargardt disease (STGD1) completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• Zimura (ARC1905)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Stargardt's Macular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2026-03-12